Oragenics to Acquire Assets of Odyssey Health to Expand Product Pipeline.

MANews-(C)2009-2023

US-based medical company Oragenics, Inc. (NYSE American: OGEN) has agreed to acquire all assets of pharmaceutical-focussed development-stage company Odyssey Health, Inc. (OTCQB: ODYY) related to its proprietary neurological drug therapies and technologies, the company said.

The asset purchase includes cash payments to Odyssey totaling USD 1m and 8m shares of Oragenics' Series F convertible preferred stock.

The transaction is expected to close in the fourth quarter of 2023.

The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C, as well as Odyssey's proprietary powder formulation and its nasal...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT